Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Genmab AS stock

Learn how to easily invest in Genmab AS stock.

Genmab AS is a biotechnology business based in the US. Genmab AS shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Genmab AS employs 1,445 staff and has a trailing 12-month revenue of around $10.2 billion.

How to buy shares in Genmab AS

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GMAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Genmab AS stock price (NASDAQ: GMAB)

Use our graph to track the performance of GMAB stocks over time.

Genmab AS shares at a glance

Information last updated 2022-09-26.
Latest market close$31.52
52-week range$26.19 - $47.28
50-day moving average $35.67
200-day moving average $34.42
Wall St. target price$41.53
PE ratio 41.8816
Dividend yield $0 (0%)
Earnings per share (TTM) $0.76

Buy Genmab AS shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Genmab AS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genmab AS price performance over time

Historical closes compared with the close of $31.52 from 2022-09-26

1 week (2022-09-20) -9.37%
1 month (2022-08-26) -10.30%
3 months (2022-06-28) 0.25%
6 months (2022-03-28) -12.52%
1 year (2021-09-28) -25.04%
2 years (2020-09-28) -14.70%
3 years (2019-09-27) 59.43%
5 years (2017-09-27) 109.724

Is Genmab AS stock undervalued or overvalued?

Valuing Genmab AS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab AS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Genmab AS's P/E ratio

Genmab AS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Genmab AS shares trade at around 42x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Genmab AS's PEG ratio

Genmab AS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2081. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab AS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Genmab AS's EBITDA

Genmab AS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.7 billion.

The EBITDA is a measure of a Genmab AS's overall financial performance and is widely used to measure a its profitability.

Genmab AS financials

Revenue TTM $10.2 billion
Operating margin TTM 33.89%
Gross profit TTM $8.5 billion
Return on assets TTM 8.66%
Return on equity TTM 17.71%
Profit margin 38.81%
Book value $37.44
Market capitalisation $21.7 billion

TTM: trailing 12 months

Genmab AS share dividends

We're not expecting Genmab AS to pay a dividend over the next 12 months.

Have Genmab AS's shares ever split?

Genmab AS's shares were split on a 5:1 basis on 1 May 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab AS shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab AS shares which in turn could have impacted Genmab AS's share price.

Genmab AS share price volatility

Over the last 12 months, Genmab AS's shares have ranged in value from as little as $26.19 up to $47.28. A popular way to gauge a stock's volatility is its "beta".

GMAB.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab AS's is 0.6243. This would suggest that Genmab AS's shares are less volatile than average (for this exchange).

Genmab AS overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

Frequently asked questions

What percentage of Genmab AS is owned by insiders or institutions?
Currently 0.009% of Genmab AS shares are held by insiders and 5.511% by institutions.
How many people work for Genmab AS?
Latest data suggests 1,445 work at Genmab AS.
When does the fiscal year end for Genmab AS?
Genmab AS's fiscal year ends in December.
Where is Genmab AS based?
Genmab AS's address is: Kalvebod Brygge 43, Copenhagen, Denmark, 1560
What is Genmab AS's ISIN number?
Genmab AS's international securities identification number is: US3723032062
What is Genmab AS's CUSIP number?
Genmab AS's Committee on Uniform Securities Identification Procedures number is: 372303206

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site